133 related articles for article (PubMed ID: 15887956)
1. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.
Ward SE; Harrington FP; Gordon LJ; Hopley SC; Scott CM; Watson JM
J Med Chem; 2005 May; 48(10):3478-80. PubMed ID: 15887956
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.
Zhou D; Stack GP; Lo J; Failli AA; Evrard DA; Harrison BL; Hatzenbuhler NT; Tran M; Croce S; Yi S; Golembieski J; Hornby GA; Lai M; Lin Q; Schechter LE; Smith DL; Shilling AD; Huselton C; Mitchell P; Beyer CE; Andree TH
J Med Chem; 2009 Aug; 52(15):4955-9. PubMed ID: 19719241
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
Lovell PJ; Blaney FE; Goodacre CJ; Scott CM; Smith PW; Starr KR; Thewlis KM; Vong AK; Ward SE; Watson JM
Bioorg Med Chem Lett; 2007 Feb; 17(4):1033-6. PubMed ID: 17129726
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
Hatzenbuhler NT; Evrard DA; Harrison BL; Huryn D; Inghrim J; Kraml C; Mattes JF; Mewshaw RE; Zhou D; Hornby G; Lin Q; Smith DL; Sullivan KM; Schechter LE; Beyer CE; Andree TH
J Med Chem; 2006 Jul; 49(15):4785-9. PubMed ID: 16854086
[TBL] [Abstract][Full Text] [Related]
5. SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
Scott C; Soffin EM; Hill M; Atkinson PJ; Langmead CJ; Wren PB; Faedo S; Gordon LJ; Price GW; Bromidge S; Johnson CN; Hagan JJ; Watson J
Eur J Pharmacol; 2006 Apr; 536(1-2):54-61. PubMed ID: 16571351
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.
Ward SE; Eddershaw PJ; Scott CM; Gordon LJ; Lovell PJ; Moore SH; Smith PW; Starr KR; Thewlis KM; Watson JM
J Med Chem; 2008 May; 51(10):2887-90. PubMed ID: 18433113
[TBL] [Abstract][Full Text] [Related]
7. 8-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors--part II.
Bromidge SM; Bertani B; Borriello M; Bozzoli A; Faedo S; Gianotti M; Gordon LJ; Hill M; Zucchelli V; Watson JM; Zonzini L
Bioorg Med Chem Lett; 2009 Apr; 19(8):2338-42. PubMed ID: 19286377
[TBL] [Abstract][Full Text] [Related]
8. 6-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors.
Bromidge SM; Bertani B; Borriello M; Faedo S; Gordon LJ; Granci E; Hill M; Marshall HR; Stasi LP; Zucchelli V; Merlo G; Vesentini A; Watson JM; Zonzini L
Bioorg Med Chem Lett; 2008 Oct; 18(20):5653-6. PubMed ID: 18799312
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
Seo HJ; Park EJ; Kim MJ; Kang SY; Lee SH; Kim HJ; Lee KN; Jung ME; Lee M; Kim MS; Son EJ; Park WK; Kim J; Lee J
J Med Chem; 2011 Sep; 54(18):6305-18. PubMed ID: 21823597
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
[TBL] [Abstract][Full Text] [Related]
11. De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
Nugiel DA; Krumrine JR; Hill DC; Damewood JR; Bernstein PR; Sobotka-Briner CD; Liu J; Zacco A; Pierson ME
J Med Chem; 2010 Feb; 53(4):1876-80. PubMed ID: 20088516
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
Heinrich T; Böttcher H; Gericke R; Bartoszyk GD; Anzali S; Seyfried CA; Greiner HE; Van Amsterdam C
J Med Chem; 2004 Sep; 47(19):4684-92. PubMed ID: 15341484
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors.
Orús L; Pérez-Silanes S; Oficialdegui AM; Martínez-Esparza J; Del Castillo JC; Mourelle M; Langer T; Guccione S; Donzella G; Krovat EM; Poptodorov K; Lasheras B; Ballaz S; Hervías I; Tordera R; Del Río J; Monge A
J Med Chem; 2002 Sep; 45(19):4128-39. PubMed ID: 12213056
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic α₁- and serotonine 5-HT1A receptors.
Prandi A; Franchini S; Manasieva LI; Fossa P; Cichero E; Marucci G; Buccioni M; Cilia A; Pirona L; Brasili L
J Med Chem; 2012 Jan; 55(1):23-36. PubMed ID: 22145629
[TBL] [Abstract][Full Text] [Related]
16. The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.
Childers WE; Havran LM; Asselin M; Bicksler JJ; Chong DC; Grosu GT; Shen Z; Abou-Gharbia MA; Bach AC; Harrison BL; Kagan N; Kleintop T; Magolda R; Marathias V; Robichaud AJ; Sabb AL; Zhang MY; Andree TH; Aschmies SH; Beyer C; Comery TA; Day M; Grauer SM; Hughes ZA; Rosenzweig-Lipson S; Platt B; Pulicicchio C; Smith DE; Sukoff-Rizzo SJ; Sullivan KM; Adedoyin A; Huselton C; Hirst WD
J Med Chem; 2010 May; 53(10):4066-84. PubMed ID: 20443629
[TBL] [Abstract][Full Text] [Related]
17. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
18. 3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.
Atkinson PJ; Bromidge SM; Duxon MS; Gaster LM; Hadley MS; Hammond B; Johnson CN; Middlemiss DN; North SE; Price GW; Rami HK; Riley GJ; Scott CM; Shaw TE; Starr KR; Stemp G; Thewlis KM; Thomas DR; Thompson M; Vong AK; Watson JM
Bioorg Med Chem Lett; 2005 Feb; 15(3):737-41. PubMed ID: 15664848
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
Smid P; Coolen HK; Keizer HG; van Hes R; de Moes JP; den Hartog AP; Stork B; Plekkenpol RH; Niemann LC; Stroomer CN; Tulp MT; van Stuivenberg HH; McCreary AC; Hesselink MB; Herremans AH; Kruse CG
J Med Chem; 2005 Nov; 48(22):6855-69. PubMed ID: 16250644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
